- Home
- ALEC vs MOLN Comparison
ALEC vs MOLN Comparison
Compare ALEC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- MOLN
- Stock Information
- Founded
- ALEC 2013
- MOLN 2004
- Country
- ALEC United States
- MOLN Switzerland
- Employees
- ALEC N/A
- MOLN N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- MOLN
- Sector
- ALEC Health Care
- MOLN
- Exchange
- ALEC Nasdaq
- MOLN Nasdaq
- Market Cap
- ALEC 124.0M
- MOLN 142.5M
- IPO Year
- ALEC 2019
- MOLN 2021
- Fundamental
- Price
- ALEC $1.50
- MOLN $3.75
- Analyst Decision
- ALEC Hold
- MOLN Hold
- Analyst Count
- ALEC 9
- MOLN 1
- Target Price
- ALEC $3.40
- MOLN $4.00
- AVG Volume (30 Days)
- ALEC 4.6M
- MOLN 2.0K
- Earning Date
- ALEC 11-06-2025
- MOLN 03-12-2026
- Dividend Yield
- ALEC N/A
- MOLN N/A
- EPS Growth
- ALEC N/A
- MOLN N/A
- EPS
- ALEC N/A
- MOLN N/A
- Revenue
- ALEC $81,130,000.00
- MOLN $856,302.00
- Revenue This Year
- ALEC N/A
- MOLN N/A
- Revenue Next Year
- ALEC $290.64
- MOLN $1,000.00
- P/E Ratio
- ALEC N/A
- MOLN N/A
- Revenue Growth
- ALEC 46.77
- MOLN N/A
- 52 Week Low
- ALEC $0.87
- MOLN $3.36
- 52 Week High
- ALEC $6.14
- MOLN $6.63
- Technical
- Relative Strength Index (RSI)
- ALEC 27.08
- MOLN 51.45
- Support Level
- ALEC $1.45
- MOLN $3.53
- Resistance Level
- ALEC $1.60
- MOLN $3.92
- Average True Range (ATR)
- ALEC 0.20
- MOLN 0.09
- MACD
- ALEC -0.20
- MOLN -0.01
- Stochastic Oscillator
- ALEC 8.45
- MOLN 46.81
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.